Mabwell(SH:688062) Quan Jing Wang·2025-08-06 01:17Core Viewpoint - The collaboration between Maiwei Biotech's subsidiary Taikang Biotech and Qilu Pharmaceutical has garnered significant attention, focusing on the licensing agreement for the injectable drug Agrelistat α (brand name: Maili Sheng®) [1] Group 1: Collaboration Details - The licensing agreement grants Maiwei Biotech exclusive rights for Qilu Pharmaceutical to develop, produce, improve, utilize, and commercialize the licensed product in Greater China, including mainland China, Hong Kong, Macau, and Taiwan [1] - Taikang Biotech is set to receive a total of up to 500 million RMB in upfront and milestone payments, along with royalties of up to double-digit percentages of net sales from the licensed product [1] Group 2: Product Information - Agrelistat α is a recombinant human serum albumin-granulocyte colony-stimulating factor (G-CSF) fusion protein, designed to reduce the incidence of infections in adult patients with non-myeloid malignancies undergoing chemotherapy that may cause febrile neutropenia [1] - This product represents a new generation of long-acting G-CSF with independent intellectual property rights, utilizing gene fusion technology to combine high-activity modified G-CSF with human serum albumin (HSA) [2] - The fusion with HSA increases molecular weight and significantly inhibits the clearance pathway mediated by G-CSF receptors, thereby extending the drug's half-life and reducing dosing frequency, which enhances treatment compliance [2] - HSA, being a natural component of human blood, provides a high level of safety as a carrier protein, and the product is produced using a Pichia pastoris expression system, simplifying the manufacturing process compared to chemically modified long-acting products [2]